Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology | Immunology
Disease Category: Lymphoma
Location: United States, WV

Clinical Trial Details

Overview

Research Study Summary

OMB110918-A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment

Purpose

The primary objective is to test whether the ofatumumab and bendamustine combination therapy will improve disease progression-free survival in subjects with indolent B-cell NHL that did not respond (stable disease or progressive disease) to rituximab or a rituximab-containing regimen during or within 6 months of the last rituximab treatment.

To Learn more
Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Facility Type

N/A

Contact

West Virginia University - Clinical Trials Research Unit
1637 Health Sciences South, PO Box 9260
Morgantown, WV 26506
Phone: 304-293-7374

View Map

CW ID: 169036

Date Last Changed: July 23, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.